BiotechTube
CounterX Therapeutics

CounterX Therapeutics

Cambridge, United States· Est.
counterxtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CounterX Therapeutics is a preclinical-stage biotech tackling the opioid crisis with a dual-pronged approach of monoclonal antibodies and vaccines. Its lead candidate, CTRX-101, is a long-acting anti-fentanyl antibody designed to prevent accidental overdose, with an IND filing anticipated in Q2 2026. The company leverages its proprietary CounterXCL™ discovery platform, which integrates immunology, bioengineering, and AI, to develop targeted solutions for opioid dependence and overdose prevention.

Opioid Use DisorderOverdose PreventionAddiction

Technology Platform

Proprietary CounterXCL™ discovery platform leveraging immunology, chemistry, advanced bioengineering, and artificial intelligence to develop novel antibody therapeutics and vaccines targeting opioids like fentanyl.

Opportunities

The escalating fentanyl crisis, with tens of thousands of deaths annually, creates a massive and urgent unmet medical need for preventative solutions.
A long-acting prophylactic antibody could fill a critical gap in the current treatment landscape, which is dominated by short-acting emergency reversal agents.
The company's mission aligns with significant public health priorities, potentially facilitating grant funding and regulatory cooperation.

Risk Factors

High scientific risk in translating preclinical antibody and vaccine data to human safety and efficacy.
The regulatory pathway for a first-in-class prophylactic overdose treatment is novel and uncertain.
Future commercialization faces challenges in reaching and treating a high-risk, often underserved patient population.

Competitive Landscape

Competition includes approved emergency treatments like naloxone (Narcan) and medications for OUD (buprenorphine, methadone). Other biotechs and academic groups are also developing anti-opioid monoclonal antibodies and conjugate vaccines, though the field is not yet crowded. CounterX's differentiation lies in its specific focus on fentanyl and its dual-platform strategy for both therapy and prevention.

More companies in Small Molecule Drugs →More companies in United States →